Deep Brain Stimulation Devices Market for Parkinson’s Disease, By Product (Single Channel, Dual-Channel), By Region ( North America, Latin America, Europe, Asia Pacific, Middle East, Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Sep 2021

Code : CMI4627

Pages :200

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Recent Developments:

Companies are launching new deep brain stimulation devices based on new and advanced technology which can be attributed to the growth of deep brain stimulation devices market for Parkinson’s disease. For instance, in January 2021, Medtronic plc. announced the first enrollment in Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD). The clinical trials are for testing the safety and efficacy of the Percept PC device which helps in automated adjustment of brain stimulation for providing therapy and management of symptoms associated with Parkinson's disease.

In addition, the technological advancements in deep brain stimulation devices is further boosting the market growth. For instance, in March 2021, University of Houston biomedical engineer presented evidence in Nature Communications Biology that stimulation of higher frequencies (>100Hz) can induce resonating waveforms for recalibration of dysfunctional circuits. This new technology can help in treatment of Parkinson’s disease.

North America held dominant position in the global deep brain stimulation devices market for Parkinson’s disease in 2020, accounting for 37.5% share in terms of volume, followed by Europe and Asia Pacific, respectively. The rapid adoption of new deep brain stimulation devices in the region can be attributed to the market growth. For instance, in June 2021, the University of Florida Health neurosurgeons implanted Medtronic’s SenSight Directional Lead System in Parkinson’s disease patient. It is a technologically advanced deep brain stimulation system for monitoring real-time brain signals.

Global Deep Brain Stimulation Devices Market for Parkinson’s Disease: Key Developments

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in December 2019, Aleva Neurotherapeutics received CE Mark for its flagship product, the directSTIMTM Deep Brain Stimulation System.